China’s National Medical Products Administration (NMPA) has executed a series of historic regulatory clearances, spearheaded by the landmark global approval of CARsgen Therapeutics’ satricabtagene autoleucel (satri-cel). The regulatory validation establishes satri-cel as the world’s first commercially marketed CAR-T cell therapy engineered to successfully bypass the immunological barriers of solid tumors, ushering in a transformative era for cellular macro-therapeutics.
The documented clinical efficacy parameters of satri-cel in gastric oncology, the triad of co-approved first-in-class molecular innovations, and Eli Lilly’s combination approvals feature:
-
World-First Solid Tumor CAR-T Satri-cel and the Claudin18.2 Antigen Matrix:
-
Clinical Indication: Satri-cel is indicated within China for the treatment of patients diagnosed with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma who have progressed after failing at least two prior lines of systemic chemotherapy. CARsgen stands as the first global innovator to clinically validate and report the solid tumor-associated antigen Claudin18.2—a highly selective marker protein tightly restricted in healthy tissues but intensely overexpressed in gastrointestinal malignancies—as a viable homing target for engineered T-cells.
-
Survival Displacements: Disclosed at the American Society of Clinical Oncology (ASCO) Annual Meeting, satri-cel yielded profound survival benefits over standard physician’s choice chemotherapies. The cell therapy locked in a median progression-free survival (mPFS) of 3.25 months versus 1.77 months in the control arm, while median overall survival (mOS) ascended to 7.92 months compared to 5.49 months. To catalyze tumor penetration, CARsgen integrated a novel preconditioning regimen merging low-dose nab-paclitaxel chemotherapy with traditional lymphodepletion. Gastric cancer commands a crushing disease burden in Asia, with Chinese patients accounting for approximately 47% of the global caseload.
-
-
A Triad of Co-Approved First-in-Class Molecular Formulations:
-
EGFRxHER3 Bispecific ADC Iza-bren: The NMPA granted conditional approval to Sichuan Biokin Pharmaceutical’s izalontamab brengitecan (iza-bren) for advanced nasopharyngeal carcinoma. The molecule represents the world’s first bispecific antibody-drug conjugate (ADC) to clear regulatory checkpoints. Bristol Myers Squibb (BMS) previously anchored its pipeline by paying Biokin’s subsidiary, SystImmune, $800 million upfront in a potential $8,400 million licensing deal to control ex-China commercial rights.
-
Rabies Post-Exposure Prophylaxis Bispecific Silevimig: Developed by Genrix Bio (with commercial rights held by China Medical System), silevimig secured validation as the world’s first bispecific antibody designed for passive immunization during rabies post-exposure prophylaxis (PEP). Engineered to link simultaneously with dual viral epitopes, the product features low-dose efficacy, streamlined clinical administration, and high-volume industrial scalability.
-
Non-Antibiotic Antimicrobial Peptide Peceleganan: Pulai Pharmaceutical, alongside commercial partner Chia Tai Tianqing (Sino Biopharm), won marketing clearance for an anti-infective topical spray driven by peceleganan. The active ingredient introduces a non-antibiotic antimicrobial peptide (AMP) class that eradicates multi-drug resistant hospital pathogens including S. epidermidis, S. haemolyticus, and A. baumannii. The peptide bypasses traditional antibiotic paths, destroying bacterial cell membranes via electrostatic interactions and hydrophobic structural insertions on superficial wounds and burns.
-
-
Expanded Approvals for Eli Lilly’s Oral SERD Inluriyo Combinations:
-
Intersecting the infectious disease and oncology sweeps, the NMPA cleared Eli Lilly’s Inluriyo for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer cohorts with prior endocrine exposure. Inluriyo is classified as an oral selective estrogen receptor degrader (SERD).
-
While the U.S. FDA restricted Inluriyo’s initial approval to a standalone monotherapy due to immature tracking datasets, Chinese regulators moved aggressively ahead. Citing highly favorable overall survival curves, the NMPA simultaneously greenlighted the Inluriyo-Verzenio combination regimen (pairing the SERD with Lilly’s CDK4/6 inhibitor, abemaciclib) alongside its baseline monotherapy track.
-